Breast (Edinburgh, Scotland)

Keyphrases

Publications

volume 73, 2023

Yanyu Zhang, Xiaoxi Huang, Xingxing Yu, Wei He, Kamila Czene, Haomin Yang
Hematological and biochemical markers influencing breast cancer risk and mortality: Prospective cohort study in the UK Biobank by multi-state models. Breast (Edinburgh, Scotland) 73 (2023)
Maartje A C Schreurs, Teresa Ramón Y Cajal, Muriel A Adank, J Margriet Collée, Antoinette Hollestelle, Jeroen van Rooij, Marjanka K Schmidt, Maartje J Hooning
The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. Breast (Edinburgh, Scotland) 73 (2023)
T Blackmore, K Norman, V Burrett, J Scarlet, I Campbell, R Lawrenson
Key factors in the decision-making process for mastectomy alone or breast reconstruction: A qualitative analysis. Breast (Edinburgh, Scotland) 73 (2023)
Masahiro Ito, Masakazu Amari, Akiko Sato, Masahiro Hikichi, Aru Sakamoto, Asumi Yamazaki, Shigehira Saji
Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy. Breast (Edinburgh, Scotland) 73 (2023)
Matteo Ghilli, Andrea Vittorio Emanuele Lisa, Marzia Salgarello, Giovanni Papa, Mario Rietjens, Secondo Folli, Annalisa Curcio, Guglielmo Ferrari, Francesco Caruso, Vittorio Altomare, Daniele Friedman, Maria Carmen De Santis, Fiorenza De Rose, Bruno Meduri, Francesca De Felice, Lorenza Marino, Francesca Cucciarelli, Stefania Montemezzi, Pietro Panizza, Paolo Belli, Francesca Caumo, Valeriano Vinci, Giorgio De Santis, Marco Klinger, Manuela Roncella, null null
Oncoplastic and reconstructive surgery in SENONETWORK Italian breast centers: lights and shadows. Breast (Edinburgh, Scotland) 73 (2023)
Min Seo Choi, Jee Suk Chang, Kyubo Kim, Jin Hee Kim, Tae Hyung Kim, Sungmin Kim, Hyejung Cha, Oyeon Cho, Jin Hwa Choi, Myungsoo Kim, Juree Kim, Tae Gyu Kim, Seung-Gu Yeo, Ah Ram Chang, Sung-Ja Ahn, Jinhyun Choi, Ki Mun Kang, Jeanny Kwon, Taeryool Koo, Mi Young Kim, Seo Hee Choi, Bae Kwon Jeong, Bum-Sup Jang, In Young Jo, Hyebin Lee, Nalee Kim, Hae Jin Park, Jung Ho Im, Sea-Won Lee, Yeona Cho, Sun Young Lee, Ji Hyun Chang, Jaehee Chun, Eung Man Lee, Jin Sung Kim, Kyung Hwan Shin, Yong Bae Kim
Assessment of deep learning-based auto-contouring on interobserver consistency in target volume and organs-at-risk delineation for breast cancer: Implications for RTQA program in a multi-institutional study. Breast (Edinburgh, Scotland) 73 (2023)
Emma Söderberg, Fredrik Wärnberg, Anna-Karin Wennstig, Greger Nilsson, Hans Garmo, Lars Holmberg, Carl Blomqvist, Malin Sund, Charlotta Wadsten
Association of clinicopathologic variables and patient preference with the choice of surgical treatment for early-stage breast cancer: A registry-based study. Breast (Edinburgh, Scotland) 73 (2023)
Kelvin Kh Bao, Jeffrey Ch Chan, Jocelyn G Chan, Leone Sutanto, Ka Man Cheung, Harry Hy Yiu
Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Breast (Edinburgh, Scotland) 73 (2023)
Pavla Ticha, Andrej Sukop
Patient-reported outcomes in bilateral prophylactic mastectomy with breast reconstruction: A narrative review. Breast (Edinburgh, Scotland) 73 (2023)
Sandrine Hild, Delphine Teigné, Damien Fairier, Yannick Ruelle, Isabelle Aubin-Auger, Stéphanie Sidorkiewicz, Marie Citrini, Xavier Gocko, Catherine Cerisey, Emilie Ferrat, Cédric Rat
Development and evaluation of a decision aid for women eligible for organized breast cancer screening according to international standards: A multi-method study. Breast (Edinburgh, Scotland) 73 (2023)

volume 72, 2023

Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li, Binghe Xu
Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial. Breast (Edinburgh, Scotland) 72 (2023)
Orit Kaidar-Person, Birgitte Vrou Offersen, Trine Tramm, Peer Christiansen, Tine Engberg Damsgaard, Ashutosh Kothari, Philip Poortmans
The King is in the altogether: Radiation therapy after oncoplastic breast surgery. Breast (Edinburgh, Scotland) 72 (2023)
Massimo Di Maio, Claudia Bighin, Francesco Schettini, Tommaso Ruelle, Laura Marandino, Alessandra Fabi, Carmine De Angelis, Mario Giuliano, Pietro De Placido, Michelino De Laurentiis, Ferdinando Riccardi, Caterina Picotto, Fabio Puglisi, Lucia Del Mastro, Grazia Arpino, null null
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study. Breast (Edinburgh, Scotland) 72 (2023)
Marcelo Antonini, André Mattar, Fernanda Grace Bauk Richter, Gabriel Duque Pannain, Marina Diógenes Teixeira, Andressa Gonçalves Amorim, Odair Ferraro, Reginaldo Coelho Guedes Lopes, Luiz Henrique Gebrim, Juliana Monte Real
Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival. Breast (Edinburgh, Scotland) 72 (2023)
Tanwiwat Jaikuna, Eliana Vasquez Osorio, David Azria, Jenny Chang-Claude, Maria Carmen De Santis, Sara Gutiérrez-Enríquez, Marcel van Herk, Peter Hoskin, Maarten Lambrecht, Zoe Lingard, Petra Seibold, Alejandro Seoane, Elena Sperk, R Paul Symonds, Christopher J Talbot, Tiziana Rancati, Tim Rattay, Victoria Reyes, Barry S Rosenstein, Dirk de Ruysscher, Ana Vega, Liv Veldeman, Adam Webb, Catharine M L West, Marianne C Aznar
Contouring variation affects estimates of normal tissue complication probability for breast fibrosis after radiotherapy. Breast (Edinburgh, Scotland) 72 (2023)
Guy Jerusalem, Aleix Prat, Roberto Salgado, Mattea Reinisch, Cristina Saura, Manuel Ruiz Borrego, Petros Nikolinakos, Felipe Ades, Jeiry Filian, Ning Huang, Antonella Mazzei-Abba, Sara M Tolaney
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. Breast (Edinburgh, Scotland) 72 (2023)
Leonor Vasconcelos de Matos, Simona Volovat, Marcio Debiasi, Fatima Cardoso
Unfolding the role of the PI3K/AKT/MTOR pathway in male breast cancer: A pragmatic appraisal. Breast (Edinburgh, Scotland) 72 (2023)
Qian Zhao, Fan Yang, Huai-Liang Wu, Miao Mo, Yun-Xiao Ling, Guang-Yu Liu
Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease. Breast (Edinburgh, Scotland) 72 (2023)
Sivaporn Pondeenana, Chao Saenghirunvattana, Patcharin Intarakhao, Sorasit Inchan, Panuwat Chuemor, Atthakorn Jarusriwanna
Additional intraoperative subpectoral plane block vs conventional pain control: A comparison of shoulder movement in patients with mastectomy. Breast (Edinburgh, Scotland) 72 (2023)
Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, Nader Hirmas, Kristina Lübbe, Mark-Oliver Zahn, Marcus Schmidt, Carsten Denkert, Ralf Lorenz, Volkmar Müller, Dirk-Michael Zahm, Christoph Mundhenke, Stefan Bauer, Marc Thill, Peter Seropian, Natalie Filmann, Sibylle Loibl
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA). Breast (Edinburgh, Scotland) 72 (2023)
Tjaša Oblak, Petra Škerl, Benjamin J Narang, Rok Blagus, Mateja Krajc, Srdjan Novaković, Janez Žgajnar
Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence. Breast (Edinburgh, Scotland) 72 (2023)
Fadila Kouhen
Omitting radiotherapy in elderly breast cancer patients: Valid strategy or illusory hope? Breast (Edinburgh, Scotland) 72 (2023)
Binliang Liu, Ning Xie, Can Tian, Ronghua Feng, Zhe-Yu Hu, Jing Li, Liping Liu, Huawu Xiao, Xiaohong Yang, Mengsi Zeng, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Tao Wu, Quchang Ouyang
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody. Breast (Edinburgh, Scotland) 72 (2023)
Manita Chaum, Sara Grossi, Jiaxi Chen, Vivian Hu, Edward Ray, Armando Giuliano, Shikha Bose
Masculinizing hormone therapy effect on breast tissue: Changes in estrogen and androgen receptors in transgender female-to-male mastectomies. Breast (Edinburgh, Scotland) 72 (2023)
Lucien E M Duijm, Luc J A Strobbe, Vivian van Breest Smallenburg, Clemence L Op de Coul-Froger, Wikke Setz-Pels, Willem Vreuls, Hermen C van Beek, Rob M G van Bommel, Adri C Voogd
Trends in the pre-operative diagnosis and surgical management of axillary lymph node metastases in women with screen-detected breast cancer. Breast (Edinburgh, Scotland) 72 (2023)
Nalee Kim, Ji-Yeon Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu, Yeon Hee Park, Haeyoung Kim
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer. Breast (Edinburgh, Scotland) 72 (2023)
Kai Cc Johnson, Michael Grimm, Jasmine Sukumar, Patrick M Schnell, Ko Un Park, Daniel G Stover, Sachin R Jhawar, Margaret Gatti-Mays, Robert Wesolowski, Nicole Williams, Sagar Sardesai, Ashley Pariser, Preeti Sudheendra, Gary Tozbikian, Bhuvaneswari Ramaswamy, Dureti Doto, Mathew A Cherian
Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls. Breast (Edinburgh, Scotland) 72 (2023)
Anbok Lee, Taewoo Kang, Su Hwan Kang, Woo-Chan Park, Woosung Lim, Myung-Chul Chang, Hyun Yul Kim, Jeong-Yoon Song, Jihyoun Lee, Kyung Do Byun, Hyun-Ah Kim, Gil Soo Son, Ju-Yeon Kim, Se Jeong Oh, Min Sung Chung, Young Jin Choi, Hyuk-Jai Shin, Jong Min Baek, Youngbum Yoo, Eunhae Um, Jin Hyuk Choi, Beom Seok Kwak, Min Ho Park, Suok Hyun Lee, Cheol Seung Kim, Ilkyun Lee, Je-Ryong Kim, Han Shin Lee, Cheol Wan Lim
An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer. Breast (Edinburgh, Scotland) 72 (2023)
M E Brennan, K Bell, G Hamid, J Gilchrist, J Gillingham
Consumer experiences of shame in clinical encounters for breast cancer treatment. "Who do you think you are- Angelina Jolie?" Breast (Edinburgh, Scotland) 72 (2023)
E R Copson, J E Abraham, J P Braybrooke, D Cameron, S A McIntosh, C O Michie, A F C Okines, C Palmieri, F Raja, R Roylance, S Spensley, null null
Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel. Breast (Edinburgh, Scotland) 72 (2023)
Jan Paredes Mogica, Haiming Tang, Yuanxin Liang, Minghao Zhong, Pei Hui, Malini Harigopal, Uma Krishnamurti, Neal A Fischbach, Haiying Zhan
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature. Breast (Edinburgh, Scotland) 72 (2023)
Benigno Acea-Nebril, Alejandra García-Novoa, Alberto Bouzón Alejandro, Carlota Díaz Carballada, Carmen Conde Iglesias
Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients. Breast (Edinburgh, Scotland) 72 (2023)
Na Li, Weiyun Gong, Yuanzhong Xie, Lei Sheng
Correlation between the CEM imaging characteristics and different molecular subtypes of breast cancer. Breast (Edinburgh, Scotland) 72 (2023)
Eric C Barat, Marianne L E Arrii, Annaelle Soubieux-Bourbon, Mikaël Daouphars, Rémi Varin, Patrick R Tilleul
Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting. Breast (Edinburgh, Scotland) 72 (2023)

volume 71, 2023

Ana-Alicia Beltran-Bless, Stephanie Kacerovsky-Strobl, Michael Gnant
Explaining risks and benefits of loco-regional treatments to patients. Breast (Edinburgh, Scotland) 71 (2023)
S Emily Bachert, Virgilius Cornea, Thérèse Bocklage
Adenosquamous proliferation in radial sclerosing lesions: Histologic spectrum and key features in systematic review of 247 lesions. Breast (Edinburgh, Scotland) 71 (2023)
Hyunjung Kim, Tae Gyu Kim, Byungdo Park, Jeong Ho Kim, Si-Youl Jun, Jun Ho Lee, Hee Jun Choi, Chang Shin Jung, Yoon Ju Bang, Hyoun Wook Lee, Jae Seok Lee, Hyun Yeol Nam, Seunghyeon Shin, Sung Min Kim, Haeyoung Kim
Effect of high-dose radiation therapy on positive margins after breast-conserving surgery for invasive breast cancer. Breast (Edinburgh, Scotland) 71 (2023)
Annemiek K E van Hemert, Frederieke H van Duijnhoven, Marie-Jeanne T F D Vrancken Peeters
This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients. Breast (Edinburgh, Scotland) 71 (2023)
A Agrawal, L Romics, D Thekkinkattil, M Soliman, M Kaushik, P Barmpounakis, C Mortimer, C A Courtney, A Goyal, E Garreffa, A Carmichael, R A Lane, C Rutherford, B Kim, R Achuthan, V Pitsinis, S Goh, B Ray, K Grover, R Vidya, J Murphy, null null
'PartBreCon' study. A UK multicentre retrospective cohort study to assess outcomes following PARTial BREast reCONstruction with chest wall perforator flaps. Breast (Edinburgh, Scotland) 71 (2023)
Kathy Dempsey, Erin Mathieu, Meagan Brennan, Kylie Snook, Julia Hoffman, Ian Campbell, Jenni Scarlet, Heather Flay, April Wong, Frances Boyle, Madeleine King, Andrew Spillane
Patient-reported health-related quality of life outcomes following mastectomy for breast cancer, with immediate, delayed or no breast reconstruction: Four-year follow-up from a prospective cohort study. Breast (Edinburgh, Scotland) 71 (2023)
Marco Driutti, Luigino Dal Maso, Federica Toffolutti, Giulia Valdi, Ettore Bidoli, Fabiola Giudici, Maria Parpinel, Diego Serraino
Breast cancer deaths attributable to alcohol consumption: Italy, 2015-2019. Breast (Edinburgh, Scotland) 71 (2023)
Keris Poelhekken, Yixuan Lin, Marcel J W Greuter, Bert van der Vegt, Monique Dorrius, Geertruida H de Bock
The natural history of ductal carcinoma in situ (DCIS) in simulation models: A systematic review. Breast (Edinburgh, Scotland) 71 (2023)
Yaning He, Yingbo Shao, Qi Chen, Chaojun Liu, Fangyuan Zhu, Hui Liu
Brain metastasis in de novo stage IV breast cancer. Breast (Edinburgh, Scotland) 71 (2023)
Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål, Bo Nordenskjöld
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. Breast (Edinburgh, Scotland) 71 (2023)
Serena Di Cosimo, Silva Ljevar, Annalisa Trama, Alice Bernasconi, Paolo Lasalvia, Maria Carmen De Santis, Vera Cappelletti, Rosalba Miceli, Giovanni Apolone
Direct and indirect effects of COVID-19 on short-term mortality of breast cancer patients. Breast (Edinburgh, Scotland) 71 (2023)
Santiago Terán, Manuel Alva, Pablo Tolosa, Macarena Rey-Cárdenas, Ainhoa Madariaga, Laura Lema, Yolanda Ruano, Luis Manso, Eva Ciruelos, Rodrigo Sánchez-Bayona
Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer. Breast (Edinburgh, Scotland) 71 (2023)
Alberto Zambelli, Marina Cazzaniga, Nicla La Verde, Elisabetta Munzone, Ippazio Cosimo Antonazzo, Lorenzo Giovanni Mantovani, Serena Di Cosimo, Anna Mancuso, Daniele Generali, Paolo Angelo Cortesi
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy. Breast (Edinburgh, Scotland) 71 (2023)
Wei Chen, Fen-Xiang Li, Da-Lin Lu, Jun Jiang, Junjie Li
Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy. Breast (Edinburgh, Scotland) 71 (2023)
Fabiana Christina Araújo Pereira Lisboa, Régis Resende Paulinelli, Lucimara Priscila Campos Veras, Luiz Fernando Jubé Ribeiro, Luis Fernando Pádua Oliveira, Rosemar Macedo Sousa Rahal, Aloisio Garcia Sousa, Ruffo Freitas-Júnior, João Batista de Sousa
Aesthetic results were more satisfactory after oncoplastic surgery than after total breast reconstruction according to patients and surgeons. Breast (Edinburgh, Scotland) 71 (2023)
Haizhu Chen, Xiaoyan Qian, Yunxia Tao, Daquan Wang, Ying Wang, Yunfang Yu, Herui Yao
Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials. Breast (Edinburgh, Scotland) 71 (2023)